Latest News and Press Releases

ROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed...

ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed...

- Objetivo de 92 pacientes evaluables (46 en la rama de control y 46 en la rama de tratamiento con VCN-01) inscritos en 15 centros de España y EE. UU. en un plazo de 21 meses – ROCKVILLE, Maryland,...

- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months – ROCKVILLE, Md., Sept. 23, 2024 (GLOBE...

ROCKVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) a diversified clinical-stage company developing therapeutics designed to...

ROCKVILLE, Maryland, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX) («Theriva» o la «Empresa»), una empresa diversificada de fase clínica que desarrolla terapias...

ROCKVILLE, Md., Aug. 17, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar enfermedades...

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of...

- Se espera que la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico (PDAC), finalice en el tercer...

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of...